Zhong L-P, Zhu H-G, Zhang C-P, Chen W-T, Zhang Z-Y
Department of Oral and Maxillofacial Surgery, Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, China.
Int J Oral Maxillofac Surg. 2007 Mar;36(3):230-4. doi: 10.1016/j.ijom.2006.06.016. Epub 2006 Sep 11.
Oral squamous cell carcinoma (OSCC) is the most common malignant tumour in the oral and maxillofacial region, and has a poor prognosis. Cyfra 21-1 is a useful tumour marker for squamous cell carcinoma, but the clinical value of Cyfra 21-1 in OSCC has not been confirmed. In order to investigate the diagnostic and prognostic value of serum Cyfra 21-1 in primary OSCC patients, the preoperative serum Cyfra 21-1 concentration of 100 OSCC patients and 56 healthy subjects was detected by enzyme-linked immunosorbent assay (ELISA). The cut-off value was calculated with a receiver operating characteristic (ROC) curve, and prognostic analysis was performed using the Kaplan-Meier method and Cox regression models. The preoperative serum Cyfra 21-1 concentration in OSCC patients (1.18+/-1.20 microg/L) was significantly higher (t=6.585, P<0.001) than that in healthy subjects (0.40+/-0.16 microg/L). With a cut-off value of 0.65 microg/L, the diagnostic sensitivity and specificity was 0.570 and 0.964, respectively. There was significant correlation with tumour recurrence and survival rate: the higher the serum Cyfra 21-1; the higher the tumour recurrence rate and lower the survival rate. Serum Cyfra 21-1 was an independent prognostic factor for OSCC using univariate and multivariate Cox models.
口腔鳞状细胞癌(OSCC)是口腔颌面部最常见的恶性肿瘤,预后较差。细胞角蛋白19片段(Cyfra 21-1)是一种用于鳞状细胞癌的有用肿瘤标志物,但Cyfra 21-1在OSCC中的临床价值尚未得到证实。为了研究血清Cyfra 21-1在原发性OSCC患者中的诊断和预后价值,采用酶联免疫吸附测定(ELISA)检测了100例OSCC患者和56例健康受试者术前血清Cyfra 21-1的浓度。用受试者工作特征(ROC)曲线计算临界值,并采用Kaplan-Meier法和Cox回归模型进行预后分析。OSCC患者术前血清Cyfra 21-1浓度(1.18±1.20μg/L)显著高于健康受试者(0.40±0.16μg/L)(t=6.585,P<0.001)。临界值为0.65μg/L时,诊断敏感性和特异性分别为0.570和0.964。血清Cyfra 21-1与肿瘤复发和生存率显著相关:血清Cyfra 21-1越高,肿瘤复发率越高,生存率越低。单因素和多因素Cox模型分析显示,血清Cyfra 21-1是OSCC的独立预后因素。